---
document_datetime: 2026-01-09 15:30:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/onureg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: onureg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.727387
conversion_datetime: 2026-01-10 11:26:45.955211
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Onureg

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA / EMA/VR/0000315025 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- | 18/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | significant in-process test - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000289529   | - Renewal - Accepted Renewal of marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/11/2025 | 08/01/2026 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Onureg in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. In the frame of this renewal and as a result of analysis of Serious Adverse Events, section 4.8 has been updated to include ADRs for sepsis and neutropenic sepsis with a common and uncommon frequency respectively |
| Variation type IB / EMA/VR/0000291593 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent                                                                                                                                                                                                                                                                                                               | 14/10/2025 | 08/01/2026 | SmPC and PL | To include the adverse reaction 'differentiation syndrome' in sections 4.4 and 4.8 of the SmPC following the assessment in EMEA/H/C/PSUSA/00010935/202405. The package leaflet is updated accordingly. In addition the MAH has amended the wording for tabulated list of                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                  | authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Other variation - Accepted To include the adverse reaction 'differentiation syndrome' in sections 4.4 and 4.8 of the SmPC following the assessment in EMEA/H/C/PSUSA/00010935/202405. The package leaflet is updated accordingly. In addition the MAH has amended the wording for tabulated list of adverse reactions in section 4.8 of the SmPC.   |            |            |    | adverse reactions in section 4.8 of the SmPC.   |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-------------------------------------------------|
| Article 61(3) / EMA/N/0000245924 | - - Accepted Update of the package leaflet to introduce a list of local representatives.                                                                                                                                                                                                                                                                                                                                | 17/02/2025 | 08/01/2026 | PL |                                                 |